van Oorschot, Desirée A M http://orcid.org/0000-0002-0382-0333
Hunjan, Manjit
Bracke, Benjamin
Lorenc, Stéphane
Curran, Desmond http://orcid.org/0000-0002-7423-0111
Starkie-Camejo, Helen
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
https://doi.org/10.1136/annrheumdis-2021-221244
Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares
https://doi.org/10.1136/annrheumdis-2019-216639
AB1596 REAL-LIFE STUDY OF IMMUNOGENECITY AND SAFETY OF THE RECOMBINANT VACCINE AGAINST VARICELLA ZOSTER VIRUS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH JANUS KINASE INHIBITORS
https://doi.org/10.1136/annrheumdis-2023-eular.5604
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
https://doi.org/10.1136/bmjopen-2018-025553
Documents that mention this clinical trial
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
https://doi.org/10.1136/annrheumdis-2021-221244
Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares
https://doi.org/10.1136/annrheumdis-2019-216639
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
https://doi.org/10.1136/bmjopen-2018-025553
Funding for this research was provided by:
GlaxoSmithKline